Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Burroughs-welcome era (BW)
3. Millenium (LeukosSite)-ilex era (MI)
4. Campath-1H: main difference between BW and MI
5. BW era results
6. BW era results study 005
7. Infectious toxicities: Campath in 005 and 009
8. MI era results: study 211
9. Campath study 211
10. Campath-1H: most common adverse events
11. Campath for patients with B-CLL: pivotal trial
12. Efficacy of Campath in trials
13. Bone marrow biopsy specimens
14. Campath pivotal trial: overall survival
15. Infectious complications after Campath treatment
16. CMV reactivation following treatment with Campath
17. CMV guidelines
18. CALGB 19901
19. Frontline flud-(iv) Campath CALGB trial
20. Trial: Moreton et al., JCO 2005
21. Trial: Moreton 2005

Topics Covered

• Development of Campath-1H
• Burroughs-Wellcome Era (BW)
• Millenium (LeukosSite)-Ilex Era (MI)
• Differences between BW era and MI era
• The two main trials in the BW era: study 005 in European countries and study 009 in the USA
• Responses to these trials
• Complications of these trials: opportunistic infection
• MI era results from 1998 and study 211 (which incorporated prophylaxis against opportunistic infections)
• Efficacy of Campath-1H
• Examination of bone marrow biopsy specimens
• Survival times
• Infectious complications after first-line therapy with Campath-1H
• CMV guidelines
• CALGB trial

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 22, 2016

Financial Disclosures

• Prof. Kanti Rai has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.